Tg Therapeutics (TGTX) Profit After Tax (2011 - 2026)

Tg Therapeutics' Profit After Tax history runs 16 years deep, the most recent figure standing at $19.8 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 290.85% year-over-year to $19.8 million in Q1 2026; TTM through Mar 2026 was $461.9 million, a 1079.81% increase from a year earlier, with the FY2025 full-year figure at $447.2 million, up 1812.41% from the prior year.
• Profit After Tax declined to $19.8 million in Q1 2026 per TGTX's latest filing, from $23.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $390.9 million in Q3 2025 and bottomed at -$78.5 million in Q4 2022.
• The 5-year median for Profit After Tax is $3.9 million (2024), against an average of $16.4 million.
• Across the five-year window, Profit After Tax sank 96.59% in 2024 and surged 9974.61% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$78.5 million in 2022, then surged by 81.63% to -$14.4 million in 2023, then soared by 261.84% to $23.3 million in 2024, then retreated by 1.26% to $23.0 million in 2025, then dropped by 14.15% to $19.8 million in 2026.
• Per Business Quant, the three latest TGTX Profit After Tax figures stand at $19.8 million (Q1 2026), $23.0 million (Q4 2025), and $390.9 million (Q3 2025).